-
Tytuł:
-
Bio-Engineering of Pre-Vascularized Islet Organoids for the Treatment of Type 1 Diabetes.
-
Autorzy:
-
Wassmer CH; Laboratory of Tissue Engineering and Organ Regeneration, Department of Surgery, University of Geneva, Geneva, Switzerland.; Cell Isolation and Transplantation Center, Department of Surgery, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.; Faculty Diabetes Center, University of Geneva Medical Center, University of Geneva, Geneva, Switzerland.
Lebreton F; Laboratory of Tissue Engineering and Organ Regeneration, Department of Surgery, University of Geneva, Geneva, Switzerland.; Cell Isolation and Transplantation Center, Department of Surgery, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.; Faculty Diabetes Center, University of Geneva Medical Center, University of Geneva, Geneva, Switzerland.
Bellofatto K; Laboratory of Tissue Engineering and Organ Regeneration, Department of Surgery, University of Geneva, Geneva, Switzerland.; Cell Isolation and Transplantation Center, Department of Surgery, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.; Faculty Diabetes Center, University of Geneva Medical Center, University of Geneva, Geneva, Switzerland.
Perez L; Laboratory of Tissue Engineering and Organ Regeneration, Department of Surgery, University of Geneva, Geneva, Switzerland.; Cell Isolation and Transplantation Center, Department of Surgery, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.; Faculty Diabetes Center, University of Geneva Medical Center, University of Geneva, Geneva, Switzerland.
Cottet-Dumoulin D; Cell Isolation and Transplantation Center, Department of Surgery, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.; Faculty Diabetes Center, University of Geneva Medical Center, University of Geneva, Geneva, Switzerland.
Andres A; Cell Isolation and Transplantation Center, Department of Surgery, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Bosco D; Cell Isolation and Transplantation Center, Department of Surgery, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.; Faculty Diabetes Center, University of Geneva Medical Center, University of Geneva, Geneva, Switzerland.
Berney T; Laboratory of Tissue Engineering and Organ Regeneration, Department of Surgery, University of Geneva, Geneva, Switzerland.; Cell Isolation and Transplantation Center, Department of Surgery, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Othenin-Girard V; Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Martinez De Tejada B; Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Cohen M; Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Olgasi C; Department of Health Sciences, University of Piemonte Orientale, Novara, Italy.
Follenzi A; Department of Health Sciences, University of Piemonte Orientale, Novara, Italy.
Berishvili E; Laboratory of Tissue Engineering and Organ Regeneration, Department of Surgery, University of Geneva, Geneva, Switzerland.; Cell Isolation and Transplantation Center, Department of Surgery, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.; Faculty Diabetes Center, University of Geneva Medical Center, University of Geneva, Geneva, Switzerland.; Institute of Medical and Public Health Research, Ilia State University, Tbilisi, Georgia.
-
Corporate Authors:
-
VANGUARD Consortium
-
Źródło:
-
Transplant international : official journal of the European Society for Organ Transplantation [Transpl Int] 2022 Jan 21; Vol. 35, pp. 10214. Date of Electronic Publication: 2022 Jan 21 (Print Publication: 2021).
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 2022- : Lausanne, Switzerland : Frontiers Media S. A.
Original Publication: [Heidelberg, FRG] : Springer International, 1988-
-
MeSH Terms:
-
Diabetes Mellitus, Type 1*/surgery
Islets of Langerhans*/cytology
Tissue Engineering*
Epithelial Cells/*cytology
Human Umbilical Vein Endothelial Cells/*cytology
Animals ; Bioengineering ; Endothelial Cells ; Humans ; Insulin/metabolism ; Islets of Langerhans Transplantation ; Mice ; Organoids/physiology ; Rats
-
References:
-
World J Transplant. 2017 Apr 24;7(2):117-128. (PMID: 28507914)
Diabetologia. 2018 Jun;61(6):1273-1276. (PMID: 29511779)
Science. 2001 Oct 19;294(5542):564-7. (PMID: 11577200)
Sci Rep. 2018 Feb 8;8(1):2671. (PMID: 29422650)
Curr Diab Rep. 2017 Jun;17(6):37. (PMID: 28432571)
Am J Transplant. 2013 Oct;13(10):2550-7. (PMID: 24010969)
Diabetes. 2003 Jan;52(1):124-32. (PMID: 12502502)
Nat Protoc. 2007;2(3):481-5. (PMID: 17406610)
J Cell Mol Med. 2015 Aug;19(8):1836-46. (PMID: 25782016)
Transplantation. 2012 Aug 27;94(4):319-24. (PMID: 22814331)
Cell Stem Cell. 2018 Jun 01;22(6):810-823. (PMID: 29859172)
Lab Chip. 2019 Mar 13;19(6):948-958. (PMID: 30719525)
Diabetes. 2005 Aug;54(8):2287-93. (PMID: 16046293)
J Biol Chem. 2001 Jul 6;276(27):25279-86. (PMID: 11309388)
FASEB J. 2016 Feb;30(2):748-60. (PMID: 26534832)
Am J Transplant. 2020 Jun;20(6):1551-1561. (PMID: 32031745)
Curr Diab Rep. 2020 Jun 10;20(8):31. (PMID: 32519069)
Diabetes. 2007 Mar;56(3):594-603. (PMID: 17327426)
Islets. 2009 Jul-Aug;1(1):2-9. (PMID: 21084843)
Diabetologia. 2018 Sep;61(9):2016-2029. (PMID: 29971529)
Cell Metab. 2006 Mar;3(3):153-65. (PMID: 16517403)
Nat Commun. 2019 Oct 3;10(1):4491. (PMID: 31582751)
Q J Exp Physiol. 1985 Jul;70(3):347-56. (PMID: 3898188)
Mech Dev. 2003 Jan;120(1):65-80. (PMID: 12490297)
Diabetes Care. 2016 Jul;39(7):1230-40. (PMID: 27208344)
Vasc Endovascular Surg. 2005 Jul-Aug;39(4):293-306. (PMID: 16079938)
ASAIO J. 2021 Apr 1;67(4):370-381. (PMID: 32826394)
Diabetes. 2009 Oct;58(10):2175-84. (PMID: 19794074)
J Tissue Eng Regen Med. 2017 Jan;11(1):109-120. (PMID: 24737702)
Cell Transplant. 2020 Jan-Dec;29:963689720937292. (PMID: 32749168)
Int J Mol Med. 2017 Apr;39(4):918-926. (PMID: 28259958)
Genes Dev. 1998 Jun 15;12(12):1763-8. (PMID: 9637677)
Stem Cell Rev Rep. 2022 Jan;18(1):346-359. (PMID: 34613550)
Transpl Int. 2011 Feb;24(2):175-83. (PMID: 20819197)
Lab Invest. 2010 Nov;90(11):1661-75. (PMID: 20697378)
EBioMedicine. 2016 Oct;12:255-262. (PMID: 27592597)
Artif Cells Nanomed Biotechnol. 2018;46(sup2):431-440. (PMID: 29687742)
Diabetes. 1982 Oct;31(10):883-9. (PMID: 6759221)
Stem Cells. 2017 Jun;35(6):1493-1504. (PMID: 28276602)
Transpl Int. 2020 Dec;33(12):1577-1588. (PMID: 32852858)
Sci Rep. 2017 Jun 1;7(1):2661. (PMID: 28572610)
Sci Transl Med. 2020 Jan 15;12(526):. (PMID: 31941825)
Eur J Endocrinol. 2015 Nov;173(5):R165-83. (PMID: 26036437)
Stem Cells Int. 2019 Nov 20;2019:5432301. (PMID: 31827529)
Int Wound J. 2013 Oct;10(5):493-500. (PMID: 23902526)
-
Contributed Indexing:
-
Investigator: C Borsotti; S Merlin; L Piemonti; A Citro; S Pellegrini; J Seissler; L Wolf-van Buerck; M Honarpisheh; O Thaunat; E Massey; A Cronin; E Bunnik; D de Jongh; L Segantini; G Rossi; P Kugelmeier; P Wolint; M Cavallaro; J Götz; J Müller
Keywords: HUVECs; human amniotic epithelial cells; prevascularized iset organoids; regenerative medicine; tissue engineering; β cell replacement therapies
-
Substance Nomenclature:
-
0 (Insulin)
-
Entry Date(s):
-
Date Created: 20220221 Date Completed: 20220302 Latest Revision: 20221013
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC8842259
-
DOI:
-
10.3389/ti.2021.10214
-
PMID:
-
35185372
-
Lack of rapid revascularization and inflammatory attacks at the site of transplantation contribute to impaired islet engraftment and suboptimal metabolic control after clinical islet transplantation. In order to overcome these limitations and enhance engraftment and revascularization, we have generated and transplanted pre-vascularized insulin-secreting organoids composed of rat islet cells, human amniotic epithelial cells (hAECs), and human umbilical vein endothelial cells (HUVECs). Our study demonstrates that pre-vascularized islet organoids exhibit enhanced in vitro function compared to native islets, and, most importantly, better engraftment and improved vascularization in vivo in a murine model. This is mainly due to cross-talk between hAECs, HUVECs and islet cells, mediated by the upregulation of genes promoting angiogenesis ( vegf-a ) and β cell function ( glp-1r , pdx1 ). The possibility of adding a selected source of endothelial cells for the neo-vascularization of insulin-scereting grafts may also allow implementation of β cell replacement therapies in more favourable transplantation sites than the liver.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Wassmer, Lebreton, Bellofatto, Perez, Cottet-Dumoulin, Andres, Bosco, Berney, Othenin-Girard, Martinez De Tejada, Cohen, Olgasi, Follenzi, Berishvili and the VANGUARD Consortium.)
